Edwards Lifesciences Corp... (EW)
71.02
-0.07 (-0.10%)
At close: Jan 14, 2025, 3:59 PM
71.04
0.03%
After-hours Jan 14, 2025, 07:00 PM EST
undefined% (undefined)
| Bid | 70.42 |
| Market Cap | 41.89B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 2.59 |
| PE Ratio (ttm) | 27.42 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 73.79 |
| Volume | 2,245,942 |
| Avg. Volume (20D) | 4,991,670 |
| Open | 71.34 |
| Previous Close | 71.09 |
| Day's Range | 70.54 - 71.72 |
| 52-Week Range | 58.93 - 96.12 |
| Beta | undefined |
About EW
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the P...
Industry Medical - Devices
Sector Healthcare
IPO Date Mar 27, 2000
Employees 19,800
Stock Exchange NYSE
Ticker Symbol EW
Website https://www.edwards.com
Analyst Forecast
According to 21 analyst ratings, the average rating for EW stock is "Hold." The 12-month stock price forecast is $78, which is an increase of 9.83% from the latest price.
Buy 42.86%
Hold 52.38%
Sell 0.00%
Next Earnings Release
Edwards Lifesciences Corporation is scheduled to release its earnings on Feb 4, 2025,
during market hours.
Analysts project revenue of $1.49B, reflecting a -2.87% YoY shrinking and earnings per share of 0.55, making a -14.06% decrease YoY.
Analysts project revenue of $1.49B, reflecting a -2.87% YoY shrinking and earnings per share of 0.55, making a -14.06% decrease YoY.
1 month ago ·
Source
+5.7%
Edwards Lifesciences shares are trading higher aft...
Unlock content with
Pro Subscription
2 months ago ·
Source
-0.37%
Edwards Lifesciences shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.
